Abstract: Objective To study and analyze the treatment effect of using human serum albumin combined with furosemide and spironolactone on ascites of elderly patients with liver cirrhosis. Methods Fifty elderly patients with liver cirrhosis related ascites admitted from January 2022 to June 2024 were randomly divided into an experimental group (n=25, treated with human serum albumin combined with furosemide and spironolactone) and a control group (n=25, treated with furosemide and spironolactone). The clinical efficacies of the two groups of treatments were compared. Results The relief time of abdominal distension (16.21±3.40 days) and the reduction time of ascites (46.80±10.27 days) in the experimental group were shorter than those of (35.24 ±4.15 days) and (95.61±13.25 days) in the control group, respectively. After treatment, the albumin (Alb) level in the experimental group was significantly higher than that in the control group (40.71±2.64 g/L vs. 33.24±3.48 g/L). In contrast, the levels of alanine aminotransferase (ALT), creatinine (Cr), and 24 hour urinary protein quantitative (NDBDL) were all significantly lower in the experimental group compared to the control group: (61.20±3.15 U/L vs. 67.91±4.25 U/L)、(73.00±10.42 mmol/L vs. 78.00±10.16 mmol/L), and (1.03±0.15 g/24 h vs. 1.58±0.14 g/24 h), respctively (P<0.05 for all comparisons). Conclusion The combination of human serum albumin, furosemide, and spironolactone has a definite effect on the treatment of ascites in elderly patients with cirrhosis.

Key words: Human serum albumin, Furosemide, Spironolactone, cirrhosis, Ascites, Clinical symptoms